These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1127 related articles for article (PubMed ID: 30030656)
1. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring. Bracht JWP; Mayo-de-Las-Casas C; Berenguer J; Karachaliou N; Rosell R Curr Oncol Rep; 2018 Jul; 20(9):70. PubMed ID: 30030656 [TBL] [Abstract][Full Text] [Related]
2. Possible applications of circulating tumor cells in patients with non small cell lung cancer. Tartarone A; Rossi E; Lerose R; Mambella G; Calderone G; Zamarchi R; Aieta M Lung Cancer; 2017 May; 107():59-64. PubMed ID: 27339469 [TBL] [Abstract][Full Text] [Related]
3. The Different Facets of Liquid Biopsy: A Kaleidoscopic View. Eslami-S Z; Cortés-Hernández LE; Cayrefourcq L; Alix-Panabières C Cold Spring Harb Perspect Med; 2020 Jun; 10(6):. PubMed ID: 31548226 [TBL] [Abstract][Full Text] [Related]
4. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141 [TBL] [Abstract][Full Text] [Related]
5. Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges. Matikas A; Syrigos KN; Agelaki S Clin Lung Cancer; 2016 Nov; 17(6):507-516. PubMed ID: 27373516 [TBL] [Abstract][Full Text] [Related]
6. Liquid biopsy: paving a new avenue for cancer research. Kurma K; Eslami-S Z; Alix-Panabières C; Cayrefourcq L Cell Adh Migr; 2024 Dec; 18(1):1-26. PubMed ID: 39219215 [TBL] [Abstract][Full Text] [Related]
7. Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer. Reina C; Šabanović B; Lazzari C; Gregorc V; Heeschen C Transl Res; 2024 Oct; 272():41-53. PubMed ID: 38838851 [TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer. Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233 [TBL] [Abstract][Full Text] [Related]
9. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Guibert N; Pradines A; Favre G; Mazieres J Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32051167 [TBL] [Abstract][Full Text] [Related]
10. Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges. Seyhan AA Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063215 [TBL] [Abstract][Full Text] [Related]
11. Advances in liquid biopsy-based markers in NSCLC. Ren XD; Su N; Sun XG; Li WM; Li J; Li BW; Li RX; Lv J; Xu QY; Kong WL; Huang Q Adv Clin Chem; 2023; 114():109-150. PubMed ID: 37268331 [TBL] [Abstract][Full Text] [Related]
12. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770 [TBL] [Abstract][Full Text] [Related]
13. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer. Tan CL; Lim TH; Lim TKh; Tan DS; Chua YW; Ang MK; Pang B; Lim CT; Takano A; Lim AS; Leong MC; Lim WT Oncotarget; 2016 Apr; 7(17):23251-62. PubMed ID: 26993609 [TBL] [Abstract][Full Text] [Related]
14. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516 [TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Li W; Liu JB; Hou LK; Yu F; Zhang J; Wu W; Tang XM; Sun F; Lu HM; Deng J; Bai J; Li J; Wu CY; Lin QL; Lv ZW; Wang GR; Jiang GX; Ma YS; Fu D Mol Cancer; 2022 Jan; 21(1):25. PubMed ID: 35057806 [TBL] [Abstract][Full Text] [Related]
16. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267 [TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation. Ren F; Fei Q; Qiu K; Zhang Y; Zhang H; Sun L J Exp Clin Cancer Res; 2024 Apr; 43(1):96. PubMed ID: 38561776 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of sensitivity and specificity of CanPatrol™ technology for detection of circulating tumor cells in patients with non-small cell lung cancer. Li J; Liao Y; Ran Y; Wang G; Wu W; Qiu Y; Liu J; Wen N; Jing T; Wang H; Zhang S BMC Pulm Med; 2020 Oct; 20(1):274. PubMed ID: 33081780 [TBL] [Abstract][Full Text] [Related]